Abstract
Background: Currently, antibodies are progressively applied in medicine for different purposes, including diagnostic and therapeutic indications. Over twenty monoclonal antibodies utilized for many therapeutic reasons from therapy of cancers, immune disorders, and osteoporosis to localized bony defects. In addition, therapeutic antibodies represented various findings in bone tissue engineering.
Objectives: The current study aims to systematically review the available literature on antibody assisted bone regeneration in animal models.
Methods: A through electronic search was conducted from January 1992 to June 2017 limited to English language publications on administrations of antibodies for bone regeneration. Data extraction was ere performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
Results: Twenty studies were selected and analyzed in this systematic review. Among these studies, six articles reported in vitro results in addition to in vivo evaluations. The data is tabulated according to the route of administrations as locally administrated antibody which includes anti-bone morphogenetic protein 2 (anti-BMP2) and systemic administrated antibodies, which include anti-sclerostin and anti- Dickkopf-1 (DKK1). Data are summarized and reported by the following variables: Type of study, types of cells for in vitro investigations, types of animal models and defects characteristics, types of scaffolds used in the defect site, duration of follow-ups; and outcomes of assessments.
Conclusions: A novel approach of administration of antibodies demonstrated promising results for bone tissue engineering. However, more investigations, particularly in larger animals, are required for their further possible clinical administration.
Keywords: Antibody, bone tissue engineering, bone regeneration, growth factor, bone defects, scaffolds.
Current Stem Cell Research & Therapy
Title:Antibody Administration for Bone Tissue Engineering: A Systematic Review
Volume: 13 Issue: 4
Author(s): Sepanta Hosseinpour, Maryam Rezai Rad, Arash Khojasteh*Homayoun H. Zadeh*
Affiliation:
- School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
- Laboratory for Immunoregulation and Tissue Engineering (LITE), Ostrow School of Dentistry, University of Southern California, Los Angeles, CA,United States
Keywords: Antibody, bone tissue engineering, bone regeneration, growth factor, bone defects, scaffolds.
Abstract: Background: Currently, antibodies are progressively applied in medicine for different purposes, including diagnostic and therapeutic indications. Over twenty monoclonal antibodies utilized for many therapeutic reasons from therapy of cancers, immune disorders, and osteoporosis to localized bony defects. In addition, therapeutic antibodies represented various findings in bone tissue engineering.
Objectives: The current study aims to systematically review the available literature on antibody assisted bone regeneration in animal models.
Methods: A through electronic search was conducted from January 1992 to June 2017 limited to English language publications on administrations of antibodies for bone regeneration. Data extraction was ere performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
Results: Twenty studies were selected and analyzed in this systematic review. Among these studies, six articles reported in vitro results in addition to in vivo evaluations. The data is tabulated according to the route of administrations as locally administrated antibody which includes anti-bone morphogenetic protein 2 (anti-BMP2) and systemic administrated antibodies, which include anti-sclerostin and anti- Dickkopf-1 (DKK1). Data are summarized and reported by the following variables: Type of study, types of cells for in vitro investigations, types of animal models and defects characteristics, types of scaffolds used in the defect site, duration of follow-ups; and outcomes of assessments.
Conclusions: A novel approach of administration of antibodies demonstrated promising results for bone tissue engineering. However, more investigations, particularly in larger animals, are required for their further possible clinical administration.
Export Options
About this article
Cite this article as:
Hosseinpour Sepanta , Rad Rezai Maryam , Khojasteh Arash *, Zadeh H. Homayoun *, Antibody Administration for Bone Tissue Engineering: A Systematic Review, Current Stem Cell Research & Therapy 2018; 13 (4) . https://dx.doi.org/10.2174/1574888X13666180207095314
DOI https://dx.doi.org/10.2174/1574888X13666180207095314 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews Diabetic Retinopathy and Angiogenesis
Current Diabetes Reviews Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology Cross-Talk Between Mesenchymal Stem/Stromal Cells and Dendritic Cells
Current Stem Cell Research & Therapy Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design Biomarkers of Diabetic Nephropathy, the Present and the Future
Current Diabetes Reviews ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Dioxin Decomposition and Detection Using Gold Based Materials
Recent Patents on Chemical Engineering RHPN1-AS1 Drives the Progression of Hepatocellular Carcinoma via Regulating miR-596/IGF2BP2 Axis
Current Pharmaceutical Design Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design C-Abl Tyrosine Kinase Signaling: A New Player in AD Tau Pathology
Current Alzheimer Research Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis
Current Molecular Pharmacology Male Contraception: An Overview of the Potential Target Events
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potentials and Cytochrome P450-Mediated Interactions Involving Herbal Products Indicated for Diabetes Mellitus
Drug Metabolism Letters Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication
Endocrine, Metabolic & Immune Disorders - Drug Targets